Navigation Links
QRxPharma Granted Additional US Patent on MoxDuo®
Date:5/23/2012

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.  This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.

"This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma's MoxDuo opioid products for the treatment of acute and chronic pain," said Dr. John Holaday, Managing Director and Chief Executive Officer.  "This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year."

The original composition of matter patent granted by the USPTO (U.S. Patent No. 6,310,072) covers the combination of morphine and oxycodone and provides coverage until 2016.  The newly issued patent is directed to a method of treatment of pain using MoxDuo's composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023.  Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

In April, QRxPharma announced the successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.  The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
(Date:12/22/2014)... , Dec. 22, 2014   TRU-D SmartUVC ... no-touch UV disinfection robot, announced today that the General ... contract through November 2019.   This newly ... engage all levels of government purchasers, including Department of ... well as Homeland Security contacts purchasing solutions for the ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 26, 2012 /PRNewswire-Asia/ -- Clearbridge BioMedics has achieved ... in-vitro diagnostic devices and today launched its ... This is one of the world,s first commercially-available ... (CTC) from blood, using biomechanical properties. The ClearCell™ ...
... ST. LOUIS, March 26, 2012   Sigma-Aldrich ® ... named one of Europe,s Top Employers by the ... of academics, business journalists, trade associations, researchers and ... assessment and acknowledgement.  Sigma-Aldrich is one of nine ...
Cached Medicine Technology:Clearbridge BioMedics Achieves ISO 13485 Certification and Launches ClearCell (TM) System for Cancer Research Markets 2Clearbridge BioMedics Achieves ISO 13485 Certification and Launches ClearCell (TM) System for Cancer Research Markets 3CRF Institute Names Sigma-Aldrich Top Employer Europe 2012 2CRF Institute Names Sigma-Aldrich Top Employer Europe 2012 3
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... Del., Sept. 14 The airline and pharmaceutical industries both provide ... dangerous if the risks are not properly calculated and dramatically lessened ... people who make and fly airplanes? , , ... webinar on the topic - Captain Ben Berman, senior research associate ...
... , , , ... President Obama in his speech to Congress and the nation ... the cost of medical malpractice and the defensive medicine that ... to control healthcare costs, and Medical Justice, a member based ...
... MONTEREY, Calif., Sept. 14 Mpex Pharmaceuticals, Inc. reported positive top ... novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow ... trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts ... dosing versus placebo. , , "It is exciting ...
... , , , CHERRY ... NVLX) announces today that results from the Company,s ongoing sponsored ... and post-plant in several species of turfgrass. In the coming ... in the Southeastern United States under conditions that are most ...
... ... to announce the launch of the myESMO Professional Networking Community, an innovative online platform ... , ... 2009 -- The European Society for Medical Oncology is today pleased to ...
... , , PLANO, Texas, Sept. ... today announced that it will conduct a free webinar Wednesday, September ... an industry perspective and highlighting recent activities and trends. The webinar ... establish and evolve HIEs. The webinar will be hosted by ...
Cached Medicine News:Health News:Webinar Explores Drug Safety Lessons Pharma Can Learn from Airline Industry 2Health News:MedEncentive and Medical Justice Announce Partnership 2Health News:MedEncentive and Medical Justice Announce Partnership 3Health News:MedEncentive and Medical Justice Announce Partnership 4Health News:Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology 2Health News:Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 2Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 3Health News:Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results 4Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 2Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 3Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 4Health News:Perot Systems Webinar to Provide Industry Perspective on Health Information Exchanges 2Health News:Perot Systems Webinar to Provide Industry Perspective on Health Information Exchanges 3
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... true automation and continuous random access ... assays for thyroid, anemia, cardiac, reproductive, ... are currently available, with infectious disease ... can simultaneously process 60 accessible samples ...
IRMA kit for detection of the cardiac marker Myoglobin...
... BioCheck Prolactin ELISA is intended for the ... This assay is useful in the diagnosis ... pituitary and hypothalamus. The BioCheck Prolactin Quantitative ... a solid phase enzyme-linked immunosorbent assay. The ...
Medicine Products: